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Introduction: Alport syndrome is a hereditary glomerulonephritis that results from the disruption of
collagen a345(IV) heterotrimerization caused by mutation in COL4A3, COL4A4 or COL4A5 genes. Many
clinical studies have elucidated the correlation between genotype and phenotype, but there is still much
ambiguity and insufﬁciency. Here, we focused on the a345(IV) heterotrimerization of a5(IV) missense
mutant as a novel factor to further understand the pathophysiology of Alport syndrome.
Methods: We selected 9 a5(IV) missense mutants with typical glycine substitutions that clinically differed
in disease progression. To quantify the trimerization of each mutant, split nanoluciferase-fused a3/a5
mutants and a4 were transfected into the cells, and intracellular and secreted heterotrimer were detected
by luminescence using an assay that we developed previously.
Results: Trimer formation and secretion patterns tended to be similar to the wild type in most of the
mutations that did not show proteinuria at a young age. On the other hand, trimer secretion was significantly reduced in all the mutations that showed proteinuria and early onset of renal failure. One of these
mutants has low ability of intracellular trimer formation, and the others had the defect of low-level
secretion. In addition, the mutant that is assumed to be nonpathogenic has similar trimer formation and
secretion pattern as wild-type a5(IV).
Conclusion: The result of cell-based a345(IV) heterotrimer formation assay was largely correlated with
clinical genotype–phenotype. These trimerization assessments provide additional phenotypic considerations and may help to distinguish between pathogenic and nonpathogenic mutations.
Kidney Int Rep (2020) 5, 718–726; https://doi.org/10.1016/j.ekir.2020.01.008
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lport syndrome is a hereditary kidney disease
caused by a mutation in the COL4A3, COL4A4, or
COL4A5 gene that encodes type IV collagen alpha 3, 4,
or 5 (a3/a4/a5[IV]), respectively, which are the major
components of the glomerular basement membrane
(GBM).1–4 Type IV collagen a3/a4/a5(IV) chains form
a345(IV) heterotrimer intracellularly. The folded heterotrimer is secreted and becomes a part of the GBM.
Any of the posttranslational a3/a4/a5-chain mutants in
Alport syndrome cannot form a345(IV) heterotrimer
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and all a chains (a3/a4/a5[IV]) are absent in the
GBM.5–7
Approximately 80% to 85% of patients with Alport
syndrome have X-linked inheritance (XLAS) of a mutation
in the COL4A5 gene on chromosome Xq26–48.8,9 There are
several large clinical studies about the correlation between
genotype and phenotype in male patients with XLAS.
These studies have shown that mutations with large
deletion (or truncated) mutations, such as nonsense and
frameshift mutations, are more severe than the missense
mutation of a5(IV) chain.10–12 Glycine-substituted type of
missense mutation in collagenous domain is most common
in XLAS; however there are many phenotypic variations
even in only glycine-substituted missense mutations.
Moreover, some male patients with XLAS with missense
mutation have positive a5(IV) expression in GBM and
show a markedly mild clinical picture.13,14
Kidney International Reports (2020) 5, 718–726
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Immunostaining of renal or skin biopsy specimens of
type IV collagen a345 have been used for predicting
the prognosis of patients with Alport syndrome.
However, pathological diagnosis can be invasive and
inconclusive, and it is not indicated for all patients
with mutations. Although the phenotype variability in
missense mutation is presumed to be due to the ability
of a345(IV) heterotrimer formation, noninvasive
methods for determining the state of a345(IV) trimer
has not yet been used. Therefore, the details of trimer
formation of a5(IV) missense mutant underlying the
patient’s phenotype are still unknown.
We previously established a system to detect
a345(IV) heterotrimer using split nanoluciferase binary
(or complementation) technology (NanoLuc BiT).15
Large BiT (LgBiT) and small (SmBiT) subunits are
fused to a5(IV) and a3(IV), respectively. In the presence of a3/a4/a5(IV) chains, a3/4/5(IV) forms a heterotrimer that is reﬂected as quantiﬁable luminescence
due to the proximity of a3(IV)-SmBiT and a5(IV)LgBiT. Moreover, a3(IV)-SmBiT, a5(IV)-LgBiT alone, or
the combination of these in the absence of a4(IV) do not
produce luminescence15; therefore, this system essentially measures the full-length a345(IV) heterotrimers
in cell-based analysis. Here, we used this system to
examine the relationship between the clinical phenotype of patients and the heterotrimer formation of
a345(IV) in a5(IV) missense mutations. Each mutant
showed a characteristic trimerization pattern and most
of which tended to correlate with the clinical phenotype. These results indicate that the evaluation of
a345(IV) trimerization could become one of the key
indicators of genotype–phenotype correlation in XLAS.
METHODS
Compliance With Ethical Standards
All procedures were reviewed and approved by the
Institutional Review Board of Kobe University School
of Medicine. Informed consent was obtained from patients or their parents.
Patients
Patients enrolled in this study were referred to Kobe
University Hospital for clinical evaluation or genetic
analysis. Most of them were followed in various local
hospitals in Japan. They were suspected as having
Alport syndrome from their pathological ﬁndings or
family histories. All clinical and laboratory ﬁndings
were obtained from the patients’ medical records at the
point when genetic analysis was performed.
Mutational Analysis
Mutational analysis of COL4A5 was performed by
targeted next-generation sequencing using a custom
Kidney International Reports (2020) 5, 718–726
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disease panel or conventional direct sequencing using
the Sanger method for all exons and exon-intron
boundaries. Regarding targeted sequencing, we
designed a custom panel for targeted sequences. The
gene list is shown in Supplementary Table S1. Nextgeneration sequencing samples were prepared using a
HaloPlex Target Enrichment System Kit (Agilent
Technologies, Santa Clara, CA) in accordance with the
manufacturer’s instructions. Ampliﬁed target libraries
were sequenced using MiSeq (Illumina, San Diego, CA)
and analyzed with SureCall (v.3.0; Agilent Technologies). Detected variants were conﬁrmed by Sanger
sequencing. Sanger sequencing for COL4A5 was performed by polymerase chain reaction and direct
sequencing of genomic DNA for all exons and exonintron boundaries. Blood samples were collected from
patients and/or family members, and genomic DNA
was isolated from peripheral blood leukocytes using
the Quick Gene Mini 80 System (Kurabo, Osaka, Japan),
in accordance with the manufacturer’s instructions. For
genomic DNA analysis, 51 exons of COL4A5 were
ampliﬁed by polymerase chain reaction, as described
previously.13 The polymerase chain reaction–ampliﬁed
products were then puriﬁed and subjected to direct
sequencing using a Dye Terminator Sequencing Kit
(Amersham Biosciences, Piscataway, NJ) with an
automatic DNA sequencer (model ABI Prism 3130;
PerkinElmer, Waltham, MA).
Plasmids
The plasmids for human COL4A3, COL4A4 and COL4A5
coding sequences prepared for the nanoluciferase
complementation system (Promega, Madison, WI) have
been previously described.15 Brieﬂy, a small fragment
(SmBiT) and a large fragment (LgBiT) are fused to
COL4A3 and COL4A5, respectively. For the C-terminal
fusion nanoluciferase assay, COL4A3 was inserted in
pFC36K SmBiT TK-neo Flexi vector and COLA5 was
inserted in pFC34K LgBiT TK-Neo Flexi vector. For the
N-terminal fusion nanoluciferase assay, COL4A3 and
COLA5 were subcloned into pFN35K SmBiT TK-neo
Flexi and pFN33K LgBiT TK-Neo Flexi vectors, respectively. For both C- and N-terminal fusion nanoluciferase, COL4A4 was subcloned into pEB multi-Hyg
vector and fused with 3FLAG tag. Mutants of COL4A5
in pFC34K LgBiT and pFN33K LgBiT were generated by
site-directed mutagenesis as previously described.16
Primer sequences are shown in Supplementary Table S2.
Cell Culture and Transfection, Luciferase Assay
HEK293T cells were obtained from the American Type
Culture Collection (Manassas, VA), and maintained in
Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% fetal bovine serum and 100-U penicillin and
719
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streptomycin in culture plates coated with Cellmatrix
type I-C. For nanoluciferase assay, cells were maintained in phenol red-free, low glucose Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal
bovine serum, 100-U penicillin and streptomycin, 2
mM glutamine, and 200 mM L-ascorbic acid 2phosphate trisodium salt.
Transient transfection of plasmid DNAs was performed using TransIT LT-1 reagent (Mirus Corp.,
Madison, WI) when cells were sub-conﬂuent using the
protocol recommended by the manufacturer. Twentyfour hours after transfection, cells were re-plated on
Falcon 96-well white/clear-bottom plates (Corning,
Corning, NY) for nanoluciferase assay, and cultured for
an additional 24 hours in the presence of 200 mM
ascorbic acid. On the day of assay, culture media were
transferred to new wells, and fresh media were added
to the cells. Nano-Glo Live Cell Assay reagent (Promega) was added to the media and cells. Luminescence
was measured using the GloMax Navigator system
(Promega).
Statistical Analysis
Statistical parameters are indicated in the ﬁgure legends. Nanoluciferase assays were performed in
quadruplicate starting from 4 separate cell cultures. All
data are presented as mean  SD. The signiﬁcance of
differences among groups was assessed using analysis
of variance with Tukey-Kramer post hoc tests. Differences with P values < 0.05 were considered statistically signiﬁcant.
RESULTS
Missense Mutations in COL4A5 and Clinical
Features
We selected 9 typical missense mutations of COL4A5 in
12 families. These mutations are substitutions of glycine
residues in Gly-X-Y repeats, including those previously
reported as pathogenic mutation.9,17–21 The information
on mutation status, family history, and clinical characteristics are shown in Table 1. Most of these patients had
hematuria or a family history of end-stage renal disease
(ESRD) and diagnosed by genetic analysis. G230C,
G869R, G1140V, and G1149V mutations were severe
cases with the onset of proteinuria at the average age of
5.3 years (n ¼ 3) and reached to ESRD at the average age
of 23.3 years (n ¼ 6) based on the available data. On the
other hand, mutations in G509R, G805R, G1000V,
G1030S, and G1143S mutations were cases without proteinuria at the age of diagnosis. Based on the available
data, the average age at ESRD with these mutations is
41.2 years (n ¼ 5). These less severe cases were not the
consequence of treatment. We also focused on G953V
mutation, which is probably a single-nucleotide
720
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polymorphism, according to the results of our numerous
gene analyses and recent study.22

a345(IV) Trimer Formation of C-Terminal-Tagged a5(IV) Mutant
To correlate the mutation in COL4A5 with its heterotrimer formation, we evaluated a345(IV) trimerization of
LgBiT C-terminal-tagged a5(IV) mutants in Table 1 using
our established split nanoluciferase (NanoLuc) complementation system. C-terminal of type IV collagen has the
noncollagenous 1 domain, which is important for initiation of trimerization. C-terminal LgBiT tag was attached
next to the noncollagenous 1 domain. Intracellular
analysis showed that all mutants can form more or equal
complexes than the wild type. G230C, G509R, G869R,
G1140V, and G1149V showed a signiﬁcant increase in
intracellular complexes compared with wild type
(>130% relative light units [RLU]) (Figure 1a). Nevertheless, their extracellular secretion was reduced except
in G509R, G805R, and G953V, whereas in G1143S,
secretion was slightly reduced (>80% RLU). The
extracellular secretion of G869R, G1000V, G1030S,
G1140V, and G1149V showed a signiﬁcant decrease
(<60% RLU) compared with wild type (Figure 1b). To
visualize the patterns of each mutant, scatterplot analysis
of the intracellular/secreted RLU ratio was performed.
The single-nucleotide polymorphism (G953V) and mutants with less severe phenotype (G509R, G805R,
G1143S), except G1000V and G1030S, showed similar
pattern as the wild type. In contrast, most mutants with
severe phenotypes (G230C, G869R, G1140V, G1149V)
were in the lower right (Figure 1c). Furthermore, complexes of all these mutants with severe phenotypes and
exceptional mild phenotypes (G1000V, G1030S) tended
to remain in the cells (>50% of the total complexes)
(Figure 1d). These data suggest that the extracellular
secretion of complexes was suppressed.
a345(IV) Trimer Formation of N-Terminal-Tagged a5(IV) Mutant
Besides C-terminal trimerization assay, we evaluated the
trimerization of mutants tagged with LgBiT at the Nterminal side. The N-terminal region of type IV collagen
is called the 7S domain, which is the end of trimerization.
Therefore, it is assumed that N-terminal analysis can
detect the ﬁnal form of the complexes. Intracellular
complex formation was signiﬁcantly decreased in G230C
mutant and increased in most mutants except G953V
compared with wild type (Figure 2a). Secreted complexes
were signiﬁcantly decreased in most mutants except
G953V and G1143S. In particular, the secretion of G230C,
G869R, G1000V, G1030S, G1140V, and G1149V complexes were signiﬁcantly decreased (<60% RLU)
compared with wild type (Figure 2b). In the scatter plot,
Kidney International Reports (2020) 5, 718–726
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Table 1. COL4A5 missense mutations and clinical details
Amino acid
change

Nucleotide

Exon

p.Gly230Cys

c.688G>T

13

p.Gly509Arg

c.1525G>C

23

Patient ID;
familial history

Gender

Hematuria

Proteinuria
age of
onset (yr)

Received treatment

17

þ

þ (3)

No

26

NA

NA

NA

þ



No
No

Gene
analysis

Age at
diagnosis
(yr)

Age at
ESRD (yr)

17

1

M

B

1 Grandfather

M

NA

2

M

B

14
13

2 Brother

M

NA

2 Maternal grandfather

M

NA

3

M

B

þ



NA

NA

NA

33

þ



No

60s

a5(IV)
expression

þa

p.Gly805Arg

c.2413G>A

30

3 Relative

M

NA

25

þ



No

p.Gly869RArg

c.2605G>A

31

4

M

B

12

þ

þ (12)

Yes

a

p.Gly1000Val

c.2999G>T

34

5 Father

M

B

37

þ



No

þb

p.Gly1030Ser

c.3088G>A

35

p.Gly1140Val

p.Gly1143Ser

c.3419G>T

c.3427G>A

38

38

p.Gly1149Val

c.3446G>T

38

p.Gly953Val

c.2858G>T

33

6 Brother

M

B

48

þ



NA

6 Nephew

M

B

20

þ



No

7 Father

M

NA

NA

NA

NA

8

M

B

2

þ

þ (1)

No
NA

20s

8 Mother’s cousin

M

NA

40

24

NA

NA

8 Mother’s cousin

M

NA

30

24

NA

NA

NA

9

M

B

9

þ



No

9 Cousin

M

NA

15

þ



No

9 Cousin

M

NA

12

þ



No

9 Maternal grandfather

M

NA

NA

NA

NA

10

M

B

5

þ



No

45

10 Grandfather

M

NA

66

49

NA

NA

NA

10 Mother’s cousin

M

NA

46

32

NA

NA

NA

10 Mother’s cousin

M

NA

43

NA

NA

NA

11 Son

M

NA

7

NA

NA

No

11 Father

M

NA

73

NA

NA

No

12 Father

M

B

23

þ

þ (NA)

NA

M

NA

26

þ

þ (NA)

NA

12 Uncle

Possibility of SNPs

ESRD, end-stage renal disease; M, male; NA, not available; SNP, single-nucleotide polymorphism.
Open circles indicate that gene analysis has been performed. þ, a5(IV) expression observed; –, a5(IV) expression not observed.
a
Staining result of renal biopsy.
b
Staining result of skin biopsy.
In the bottom row is a possible SNP found in multiple people who harbor this mutation.

single-nucleotide polymorphism (G953V) was almost the
same as the wild type, and mutants with mild phenotypes (G509R, G805R, G1143S) showed relatively similar
trends as the wild type. On the other hand, G230C, one
of the severe phenotypic mutants, was in the lower left
on scatter plot. This means that complex formation was
inhibited rather than secretion in G230C (Figure 2c).
Most of the wild-type complexes that formed up to the
N-terminus were mostly secreted (residual rate is
approximately 20%). In contrast, complexes of mutants
with severe phenotype (G869R, G1140V, G1149V) and
some mutants with mild phenotypes (G1000V, G1030S)
tended to remain in the cells (Figure 2d), which was
consistent with C-terminal analysis.
DISCUSSION
In the present study, we evaluated the trimer formation
and secretion of typical a5(IV) glycine-substituted
missense mutants. Glycine substitutions occur in
glycine-X-Y, which is a basic repeat sequence of the
collagenous domain and accounts for 85% of patients
Kidney International Reports (2020) 5, 718–726

with missense-type Alport syndrome.23 Because
glycine is the smallest amino acid that can be buried
inside the triple helix, its substitution can cause
structural abnormalities.24,25 The structure of a5(IV)
and a345(IV) triple-helix may be changed depending
on the amino acid type and position of substitution.
Although these changes probably contribute to the
phenotype variabilities of missense-type Alport syndrome, it is difﬁcult to prove the degree of structural
differences with only genetic information. There are
studies that tried to analyze the a5(IV) chain protein
state and structure. One study using the coimmunoprecipitation method detected the reduction
of a5(IV) chain with glycine substitution in a345(IV)
heterotrimer complex.26–28 Another study using circular dichroism spectroscopy showed that 2 different
types of glycine substitution within the same region
have different secondary structure of a5(IV) partial
recombinant proteins.29 Although these studies hinted
at the genotype–phenotype correlation, these studies
were relatively qualitative analysis and the number of
mutations was limited. Therefore, they are still
721
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Figure 1. a345(IV) trimer assay of clinical a5(IV) mutants with C-terminal tag. (a,b) Luminescence was measured in the cells (a) or media (b) in
HEK293T cells transiently expressing a3, a4, and C-terminal-tagged a5(IV) wild type (WT) or the indicated mutant. Error bars are the mean  SD
(n ¼ 4). *P < 0.01, **P < 0.001 versus WT (Tukey-Kramer test). (c) Scatterplot of the % relative light units (RLU) of intracellular (a)/secreted (b)
from cells expressing WT or mutant a5 chain. Solid line: Y ¼ X. (d) Intracellular residual rate calculated from the measured value of RLU of
intracellular/(intracellular þ secreted) from cells expressing WT or mutant a5(IV) chain. Error bars indicate the mean  SD (n ¼ 4). *P < 0.01,
**P < 0.001 versus WT (Tukey-Kramer test). (a–d) Black, WT; blue, possibly of single-nucleotide polymorphisms; gray, a5(IV) mutants with mild
pathology; red, a5(IV) mutants with severe pathology.

insufﬁcient to represent the complexity of actual
a345(IV) trimer formation. To address these limitations
of previous studies, we established the a345(IV) trimer
evaluation system using split nanoluciferase, and our
approach can assess the state of trimerization of many
mutants.15
In the present study, we focused on missense mutations in the broad area of collagenous domain of
a5(IV) chain that have different clinical severity. These
mutations also include those that cause different
severity despite substitutions with the same amino acid
(e.g., G805R vs. G869R) or mutations at close positions
(e.g., G1140V vs. G1143S). Figure 3 summarizes the
results of the trimer assays of 10 mutants and shows the
722

defect of these mutants. Overall, there was no association between the same amino acid substitutions or
mutations at close positions. The following is a discussion of each mutant.
G230C
Intracellular complex formation was decreased in the
N-terminal trimer assay. a345(IV) trimerization is
initiated by the assembly of C-terminal noncollagenous
1 domain. G230C was partially trimerized on the Cterminal side, but not on the N-terminal side. As a
result, a345(IV) secretion was greatly reduced, and this
result correlated with the severe phenotype of the patients. The mean age at ESRD is 21.5 years (n ¼ 2), with
Kidney International Reports (2020) 5, 718–726

M Kamura et al.: Trimerization of COL4A5 Mutants in Alport Syndrome

TRANSLATIONAL RESEARCH

Figure 2. a345 (IV) trimer assay of clinical a5(IV) mutants with N-terminal tag. (a,b) Luminescence was measured in the cells (a) or media (b) in
HEK293T cells transiently expressing a3, a4, and N-terminal-tagged a5(IV) WT or the indicated mutant. Error bars are the mean  SD (n ¼ 4).
*P < 0.01, **P < 0.001 versus WT (Tukey-Kramer test). (c) Scatterplot of the % relative light units (RLU) of intracellular (a)/secreted (b) from cells
expressing WT or mutant a5 chain. Solid line: Y ¼ X. (d) Intracellular residual rate calculated from the measured value of RLU of intracellular/
(intracellular þ secreted) from cells expressing WT or mutant a5(IV) chain. Error bars indicate the mean  SD (n ¼ 4). *P < 0.01, **P < 0.001
versus WT (Tukey-Kramer test). Black, WT; blue, possibly of single-nucleotide polymorphisms; gray, a5(IV) mutants with mild pathology; red,
a5(IV) mutants with severe pathology.

1 patient presenting onset of proteinuria at the age of 3
years (Table 1).
G509R, G805R, and G1143S
More than 60% of complexes were secreted extracellularly compared with wild type in both tag assays.
These mutant complexes probably retained similar
properties of the completely formed a345(IV) trimer
and had only slight inhibition of secretion. The partial
reduction correlated with clinically mild phenotypes,
that is, no early onset of proteinuria was observed
(Table 1). One of the patients with G805R missense
mutant was a5(IV) chain-positive at GBM in renal biopsy. Previous studies have conﬁrmed the expression
Kidney International Reports (2020) 5, 718–726

of a5(IV) in 29% of male patients with XLAS.13,14 In
these cases, proteinuria and end-stage renal failure
occurred signiﬁcantly in older ages. Thus, if a345(IV)
secretion is maintained to some extent, as in G509R,
G805R, and G1143S, a5(IV) expression might be positive and the phenotype is likely to be less severe.
G869R, G1000V, G1030S, G1140V, and G1149V
Intracellular complexes were increased but extracellular complexes were decreased in both N- and
C-terminal trimerization assays. These results suggest
that G869R, G1000V, G1030S, G1140V, and G1149V
have structural abnormalities within the collagenous
domain, resulting in signiﬁcant inhibition of secretion
723
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Figure 3. Trimerization and secretion behavior of a5(IV) WT and mutants. Monomers assemble at the noncollagenous 1 (NC1) domain to form
heterotrimers. Proximity of the NanoBiT (SmBiT and LgBiT) tags on trimer formation produces quantiﬁable luminescence. The scheme shows
classiﬁcation of each mutant trimerization: single-nucleotide polymorphism (blue), mutant with severe phenotype (red), and mutant with mild
phenotype (gray), by N-terminal-tag assays. WT and G953V can trimerize and are secreted normally. Mutant a5(IV) monomers that cannot be
trimerized (trimerization defect), such as G230C, are not secreted. Other variants can partially trimerize intracellularly but are not secreted
normally (secretion defect). The level of secretion may depend on the state and control mechanism of each mutant trimerization, which is likely
to affect the severity of the disease. Unsecreted monomers and complexes may be degraded by undetermined mechanisms, whereas trimerization and secretion are assumed to be important rate-limiting processes.

as a345(IV) trimers. Among them, G869R, G1140V, and
G1149V mutants present cases of severe phenotype
with proteinuria onset at 12 years old or younger based
on the available information. The secretion of G869R
complexes were markedly inhibited, and more than
80% of the complexes remained in the cells (Figures 1d
and 2d). These data from our cell-based assay revealed
obvious functional defect in G869R missense mutant
and probably show typical clinical characteristics of
the Alport syndrome phenotype. This might be a
reason that G869R is one of the highly reported mutations of Alport syndrome, and in the LOVD database
all 21 cases are classiﬁed as pathogenic (or likely
pathogenic).30
G1000V and G1030S
Contrary to our expectation, these were mutations that
inhibited a345(IV) trimer secretion in our cell-based
trimerization assay even though the patients with
G1000V and G1030S mutation did not exhibit
724

proteinuria at a young age. There are reports showing
that the median age of ESRD with G1030S mutation is
38 years.9,31 On the other hand, 1 patient with this
mutation had ESRD onset in his 20s (Table 1). The
differences in the observed severity among these patients point to a more stratiﬁed and complex clinical
picture that our assay system may not be able to predict with 100% accuracy, which is a limitation of this
assay. Although this in vitro assay system may help to
determine the pathogenicity/nonpathogenicity of the
variant, it may not be able to accurately predict the
degree of severity of the phenotype due to mitigating
or exacerbating factors existing in vivo. For G1000V,
there is a report of a5(IV) expression in skin biopsy of
benign familial hematuria with G1000V mutation. In
this study, a5(IV) was distributed diffusely but weakly
in the father and mosaically in the daughter.19 This
partial decrease in a5(IV) expression may be correlated
to our study showing that G1000V mutant complex
secretion was 56% (C-terminal tag) and 53% (NKidney International Reports (2020) 5, 718–726

TRANSLATIONAL RESEARCH

M Kamura et al.: Trimerization of COL4A5 Mutants in Alport Syndrome

terminal tag) compared with wild type. In cases when
a345(IV) trimer secretion is maintained at approximately 50%, further consideration is required to understand the degree of phenotype. As shown in our
study using the N-terminal tag assay, G1000V can
accumulate more complexes in the cell (Figure 2a).
Also, in our unpublished data, the secreted trimers
complexed at the N-terminus are relatively stable even
of mutants. Therefore, when small amounts of complexes continue to be secreted, it may be expressed as
basement membrane. However, in this study, we have
not clariﬁed whether mutant a345(IV) trimers can form
a basement membrane after secretion.
G953V
This mutation has been considered as a pathogenic
variant of Alport syndrome for a long time because it is
a typical glycine substitution.21,32–34 However, our
recent gene analysis and reports from other groups
have indicated that G953V is a single-nucleotide
polymorphism variant and is nonpathogenic.22
Consistent with those views, G953V exhibited the
same trimer formation and secretion abilities as the
wild type in our cell-based trimerization assay. We
note that G953V is the only mutant without a signiﬁcant difference in both N- and C-terminal trimer assays.
This result indicated that our cell-based assay may be
able to predict nonpathogenic mutation without
extensive genomic polymorphism analysis. Moreover,
the recent development of genetic analysis technology
has enabled comprehensive screening. Interestingly,
type IV collagen gene mutations have been frequently
found in patients with familial glomerulonephritis of
unknown cause.35 Our cell-based trimer formation
assay may become crucial in determining pathogenicity
and nonpathogenicity for novel mutations as genetic
diagnosis is advanced.
Hundreds of Alport syndrome cases and pathogenic
mutations have been reported; however, there are no
mutational hotspots, and the number of patients with
the same mutation is very limited. Furthermore, there
are different pathological interpretations, such as
pathogenic, likely pathogenic, or benign, especially in
missense mutations even with the same mutations. It
also should be noted that these previous reports
include not only individual patient differences and
partial genetic analysis results, but also that their
treatment history was unknown. Therefore, it is difﬁcult to diagnose and predict patient phenotypes using
only historical clinical databases. Although the split
nanoluciferase assessment of mutant trimerization alone
did not perfectly predict clinical severity, many trimer
characteristics assessed using this system correlated
with clinical pathology. Examining more mutants
Kidney International Reports (2020) 5, 718–726

could provide new information for existing genotype–
phenotype correlations.
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